Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Piramal starts Phase I study on diabetes compound in Canada

This article was originally published in Scrip

Executive Summary

Piramal Life Sciences, the spun-off R&D entity of the Piramal Group of India, has begun Phase I trials of an experimental compound for diabetes-metabolic syndrome in Canada. P2202, the second compound from Lilly, is being developed under a collaborative agreement between the two companies. A Phase I study of P2202 has been initiated in healthy volunteers to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound. In animal studies, P2202 was shown to lower glucose levels, triglycerides and total cholesterol, and to decrease plaque area animals with atherosclerosis. Last year, Piramal Life Sciences began a Phase I study of an orally active glucose-lowering compound (codenamed P1736) in the Netherlands.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC002214

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel